South Korea
· Delayed Price · Currency is KRW Daehan New Pharm Statistics
Total Valuation
Daehan New Pharm has a market cap or net worth of KRW 115.51 billion.
| Market Cap | 115.51B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Daehan New Pharm has 14.04 million shares outstanding.
| Shares Outstanding | 14.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -9.99% |
| Owned by Insiders (%) | 39.26% |
| Owned by Institutions (%) | 1.19% |
| Float | 8.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.12 |
| PB Ratio | 1.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.59.
| Current Ratio | 1.15 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 7.35 |
| Debt / FCF | -56.94 |
| Interest Coverage | 1.16 |
Financial Efficiency
Return on equity (ROE) is -5.45% and return on invested capital (ROIC) is 2.30%.
| Return on Equity (ROE) | -5.45% |
| Return on Assets (ROA) | 2.09% |
| Return on Capital (ROIC) | 2.30% |
| Revenue Per Employee | 238.93M |
| Profits Per Employee | -17.56M |
| Employee Count | 228 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 3.34 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.74% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.74% |
| 50-Day Moving Average | 8,835.00 |
| 200-Day Moving Average | 8,538.85 |
| Relative Strength Index (RSI) | 42.26 |
| Average Volume (20 Days) | 55,318 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daehan New Pharm had revenue of KRW 54.48 billion and -4.00 billion in losses. Loss per share was -285.93.
| Revenue | 54.48B |
| Gross Profit | 29.91B |
| Operating Income | 4.34B |
| Pretax Income | -3.45B |
| Net Income | -4.00B |
| EBITDA | 5.93B |
| EBIT | 4.34B |
| Loss Per Share | -285.93 |
Balance Sheet
The company has 1.72 billion in cash and 43.56 billion in debt, giving a net cash position of -41.84 billion or -2,981.28 per share.
| Cash & Cash Equivalents | 1.72B |
| Total Debt | 43.56B |
| Net Cash | -41.84B |
| Net Cash Per Share | -2,981.28 |
| Equity (Book Value) | 74.02B |
| Book Value Per Share | 6,012.99 |
| Working Capital | 7.52B |
Cash Flow
In the last 12 months, operating cash flow was 1.74 billion and capital expenditures -2.50 billion, giving a free cash flow of -765.05 million.
| Operating Cash Flow | 1.74B |
| Capital Expenditures | -2.50B |
| Free Cash Flow | -765.05M |
| FCF Per Share | -54.51 |
Margins
Gross margin is 54.90%, with operating and profit margins of 7.97% and -7.35%.
| Gross Margin | 54.90% |
| Operating Margin | 7.97% |
| Pretax Margin | -6.33% |
| Profit Margin | -7.35% |
| EBITDA Margin | 10.89% |
| EBIT Margin | 7.97% |
| FCF Margin | -1.40% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.22%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.22% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.45% |
| Shareholder Yield | -5.24% |
| Earnings Yield | -3.47% |
| FCF Yield | -0.66% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Daehan New Pharm has an Altman Z-Score of 1.6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.6 |
| Piotroski F-Score | n/a |